Abstract.
The nuclear factor kappa B (NF-κB) transcription factors are activated by a range of stimuli including pro-inflammatory cytokines. Active NF-κB regulates the expression of genes involved in inflammation and cell survival and aberrant NF-κB activity plays pathological roles in certain types of cancer and diseases characterized by chronic inflammation. NF-κB signaling is an attractive target for the development of novel anti-inflammatory or anti-cancer drugs and we discuss here how the method of peptide transduction has been used to specifically target NF-κB. Peptide transduction relies on the ability of certain small cell-penetrating peptides (CPPs) to enter cells, and a panel of CPP-linked inhibitors (CPP-Is) has been developed to directly inhibit NF-κB signaling. Remarkably, several of these NF-κB-targeting CPP-Is are effective in vivo and therefore offer exciting potential in the clinical setting.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
Author information
Authors and Affiliations
Corresponding author
Additional information
Received 24 April 2008; received after revision 06 June 2008; accepted 30 June 2008
Rights and permissions
About this article
Cite this article
Orange, J.S., May, M.J. Cell penetrating peptide inhibitors of Nuclear Factor-kappa B. Cell. Mol. Life Sci. 65, 3564–3591 (2008). https://doi.org/10.1007/s00018-008-8222-z
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00018-008-8222-z